title: MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
abstract: BACKGROUND
  Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis.
  
  
  METHODS
  A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible.
  
  
  RESULTS
  The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines.
  
  
  CONCLUSIONS
  The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy.
authors.affiliation: University of Connecticut, Farmington, Connecticut.
authors.forename: Rajesh V
authors.initials: RV
authors.lastname: Lalla
authors.forename: Joanne
authors.initials: J
authors.lastname: Bowen
authors.forename: Andrei
authors.initials: A
authors.lastname: Barasch
authors.forename: Linda
authors.initials: L
authors.lastname: Elting
authors.forename: Joel
authors.initials: J
authors.lastname: Epstein
authors.forename: Dorothy M
authors.initials: DM
authors.lastname: Keefe
authors.forename: Deborah B
authors.initials: DB
authors.lastname: McGuire
authors.forename: Cesar
authors.initials: C
authors.lastname: Migliorati
authors.forename: Ourania
authors.initials: O
authors.lastname: Nicolatou-Galitis
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Peterson
authors.forename: Judith E
authors.initials: JE
authors.lastname: Raber-Durlacher
authors.forename: Stephen T
authors.initials: ST
authors.lastname: Sonis
authors.forename: Sharon
authors.initials: S
authors.lastname: Elad
mesh_terms: D004999:Amifostine / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017679:Cryotherapy; D016207:Cytokines / Q000008:administration & dosage; D004941:Esophagitis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D006931:Hyperbaric Oxygenation; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage; D028022:Low-Level Light Therapy; D052016:Mucositis / Q000139:chemically induced / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy*; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D009910:Oral Hygiene; D010789:Phototherapy; D011349:Proctitis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D020011:Protective Agents / Q000627:therapeutic use*; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects*; D013280:Stomatitis / Q000139:chemically induced / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy*; D013392:Sucralfate / Q000008:administration & dosage
chemical_list: D000700:Analgesics; D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000897:Anti-Ulcer Agents; D000970:Antineoplastic Agents; D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins; D020011:Protective Agents; D011837:Radiation-Protective Agents; D013392:Sucralfate; D004999:Amifostine
keywords: Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO); gastrointestinal; guidelines; mucositis; oral; stomatitis